Clinical Trial: A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07161544) titled 'A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)' on Aug. 08.

Brief Summary: The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: Stargardt Disease

Intervention: BIOLOGICAL: AAVB-039

Single subretinal administration

Recruitment Status: NOT_YET_RECRUITING

Sponsor: AAVantgarde Bio Srl

Published by HT Digit...